Glenmark Pharma Launches Generic Lacosamide Injection in United States

ELMWOOD PARK, N.J. — Glenmark Pharmaceuticals Inc., USA, the North American subsidiary of Mumbai-based global pharmaceutical firm Glenmark Pharmaceuticals Limited, has officially launched Lacosamide Injection USP in the United States marketplace. According to regulatory filings submitted to the National Stock Exchange of India (NSE) on June 5, 2026, the newly commercialized generic medication is supplied as $200\text{ mg}/20\text{ mL}$ ($10\text{ mg}/\text{mL}$) single-dose vials.

The strategy behind this generic integration aims to capture a significant portion of the specialized clinical epilepsy market, which relies heavily on accessible intravenous anti-convulsant alternatives when oral administration is medically unfeasible.

Bioequivalence and U.S. Market Context

Lacosamide Injection USP serves as a direct bioequivalent and therapeutic equivalent to the reference listed drug (RLD), Vimpat Injection ($200\text{ mg}/20\text{ mL}$), which is developed and licensed by UCB, Inc. The active pharmaceutical ingredient (API), lacosamide, operates as an anti-convulsant indicated for the treatment of partial-onset seizures in patients aged 1 month and older. It is additionally approved as an adjunctive therapy for treating primary generalized tonic-clonic seizures in individuals aged 4 years and older.

The commercial timing of the launch addresses a vital economic pocket within hospital and institutional healthcare systems. Market intelligence metrics generated by healthcare data firm IQVIA for the 12-month period concluding in April 2026 indicate that the annual market for Vimpat Injection and its existing therapeutic equivalents generated approximately $15.2 million in domestic U.S. sales.

Portfolio Diversification and Injectable Strategy

The rollout of Lacosamide Injection USP marks a continuation of Glenmark's structural pivot toward high-margin, technically complex injectables and respiratory formulations within North America. The generic drug manufacturer has steadily scaled up its therapeutic delivery variants to insulate itself against the steep price erosion that frequently impacts standard oral solid dosage products in the United States.

According to corporate data from the U.S. Food and Drug Administration (FDA), Glenmark’s current operational portfolio consists of more than 170 distinct generic products authorized for active commercial distribution across the United States. Furthermore, the pharmaceutical firm maintains an active regulatory pipeline with roughly 40 Abbreviated New Drug Applications (ANDAs) in various phases of pending administrative review by the FDA.

Official Sources Section

The information, market statistics, and therapeutic indications provided in this news report conform directly to official corporate exchange declarations authorized by the Company Secretary and Compliance Officer of Glenmark Pharmaceuticals Limited, verified clinical listings managed on the National Stock Exchange of India, and market sizing statements published via the IQVIA National Sales Perspectives auditing index.

Quote Section

"The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to high-quality, affordable medicines."

Marc Kikuchi, President & Business Head of Glenmark North America

Why It Matters

For patients, physicians, and institutional buyers, the commercial availability of a generic alternative to Vimpat Injection provides immediate downward pressure on medical expenses within inpatient neurology units and emergency rooms. Intravenous anti-epileptic medications are vital emergency interventions for halting continuous or acute cluster seizures when a patient cannot safely swallow tablets or oral solutions.

Introducing a bioequivalent version from a large-scale manufacturer stabilizes the overall pharmaceutical supply chain, mitigating the persistent threat of hospital drug shortages while lowering the operational procurement overhead for public and private healthcare systems.

Key Facts at a Glance

• Product Specs: Lacosamide Injection USP is packaged in $200\text{ mg}/20\text{ mL}$ ($10\text{ mg}/\text{mL}$) single-dose vials for clinical intravenous administration.

• Therapeutic Target: Indicated for partial-onset seizures (patients $\ge$ 1 month old) and adjunctive care for primary generalized tonic-clonic seizures (patients $\ge$ 4 years old).

• Market Evaluation: Capturing a segment of the U.S. Vimpat market valued by IQVIA at roughly $15.2 million for the 12 months ending April 2026.

• Equivalency Rating: Fully designated as a bioequivalent and therapeutic equivalent to UCB, Inc.’s reference drug, Vimpat.

FAQ Section

What is Lacosamide Injection USP used to treat?

It is an anti-convulsant drug utilized to control partial-onset seizures and primary generalized tonic-clonic seizures. It is specifically administered intravenously in clinical settings when oral medication is not practical.

Is Glenmark’s Lacosamide Injection identical to the brand-name version?

Yes. It has been rated by the U.S. FDA as bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, matching it in strength, quality, performance, and intended usage.

How does this launch affect U.S. consumers and healthcare facilities?

By bringing a generic equivalent to market, it expands buying options for pharmacy procurement managers and medical directors. This injection option helps reduce overall institutional costs for critical epilepsy treatments.

Source: National Stock Exchange of India (NSE), U.S. Food and Drug Administration (FDA)